Neurocrine Biosciences Inc (NBIX)

Days of sales outstanding (DSO)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Receivables turnover		4.29	4.18	4.24	3.85	4.03	4.28	4.29	4.45	5.90	6.30	6.27	6.77	6.35	6.34	6.45	5.63	6.04	5.65	6.10	6.99
DSO	days	85.16	87.37	86.03	94.91	90.50	85.26	85.06	82.05	61.85	57.90	58.21	53.92	57.49	57.57	56.59	64.87	60.45	64.58	59.83	52.22

December 31, 2023 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 4.29
= 85.16

The days of sales outstanding (DSO) of Neurocrine Biosciences, Inc. have fluctuated over the past eight quarters. In Q4 2023, the DSO stood at 84.97 days, showing a slight decrease from the previous quarter's DSO of 85.49 days. However, comparing the most recent DSO with the same quarter in the previous year (85.81 days in Q4 2022), there seems to be relatively consistent performance.

Overall, the company's DSO metrics have remained within a relatively narrow range between 78.53 and 89.42 days over the past two years. This indicates that Neurocrine Biosciences, Inc. is effectively managing its accounts receivable and collecting payments from customers in a timely manner. However, it would be beneficial to monitor any trends or deviations from this range to ensure optimal cash flow management.